EIF1AX and neoplasm: EIF1AX mutations were first discovered in D3 UMs21 and in the TCGA cohort they were restricted to category 1 tumours (D3 and no 8q gain)8, while in the cohort presented by Royer-Bertrand and colleagues two of seven mutations were seen in tumours with M3 and/or 8q gain9.